title: [Comparison of screening-detected and symptomatic lung cancer patients].
abstract: Survival rates were studied in 416/27 screening-detected and 1,099/188 symptomatic patients with non-small cell lung cancer (NSCLC)/small cell lung cancer (SCLC). Screening-detected patients with both NSCLC and SCLC had earlier stage disease, showed better PS distribution, and a greater part of the patients underwent standard therapy than the symptomatic cohort with a significant difference. Median survival time, 5- and 10-year survival rates were 1,220 days, 44.4% and 34.9%, respectively, in the screening-detected patients, and 248 days, 11.3% and 7.5%, respectively, in the symptomatic patients with NSCLC. They were 584 days, 21.2% and 15.9%, respectively, in the screening-detected patients, and 257 days, 4.8% and 2.3% in the symptomatic patients with SCLC.
authors.affiliation: Dept. of Thoracic Oncology, National Cancer Center Hospital East, Chiba Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Nishiwaki
authors.forename: F
authors.initials: F
authors.lastname: Hojo
authors.forename: H
authors.initials: H
authors.lastname: Omatsu
authors.forename: K
authors.initials: K
authors.lastname: Nagai
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000401:mortality / Q000517:prevention & control; D018288:Carcinoma, Small Cell / Q000175:diagnosis* / Q000401:mortality / Q000517:prevention & control; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000517:prevention & control; D008297:Male; D008403:Mass Screening; D008875:Middle Aged; D015996:Survival Rate